Natera, Inc. (NTRA)
Nasdaq · Healthcare · Diagnostics & Research
$425.64+3.73%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $61.4B
- 52-week range
- $167.33 – $427.47
- 52-week change
- +143.49%
- EPS (trailing)
- −$1.35
- Analyst rating
- 1.4 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $2.3B (+35.90%)
- Net income
- −$208M
- Operating margin
- −13.4%
- Diluted EPS
- −$1.52
- Free cash flow
- $109M
From the company’s annual report on SEC EDGAR.
About Natera, Inc.
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model.
Headquarters: Austin, United States · 6,135 employees · natera.com